Arcadis N.V.
Amsterdam, March 12, 2021 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 72,191 of its own shares in the period from March 5, 2021 up to and including March 11, 2021 at an average price of €29.20. The consideration of this repurchase was €2.1 million. The repurchase is in accordance with the share buyback program to cover existing obligations under employee incentive plans and to cover commitments for stock dividend, as announced on 19 February 2021.
The total number of shares repurchased under this program to date is 324,721 shares for a total consideration of €9.3 million.
For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/
-End-
Improving quality of life
FOR FURTHER INFORMATION PLEASE CONTACT:
ARCADIS INVESTOR RELATIONS
Jurgen Pullens
Mobile: +31 6 51599483
E-mail: jurgen.pullens@arcadis.com
ABOUT ARCADIS
Arcadis is the leading global design & consultancy organization for natural and built assets. We maximize impact for our clients and the communities they serve by providing effective solutions through sustainable outcomes, focus and scale, and digitalization. We are over 27,000 people, active in more than 70 countries that generate €3.3 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com
REGULATED INFORMATION
This press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Attachments
- Arcadis reports transactions under its current share buyback program week 3
- Arcadis share buy back program 2021
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ALK Abello19.12.2025 22:46:46 CET | Press release
Major shareholder announcement
ALK Abello19.12.2025 22:46:46 CET | Pressemeddelelse
Storaktionærmeddelelse
Zealand Pharma19.12.2025 22:00:00 CET | Press release
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Boehringer Ingelheim Limited19.12.2025 21:10:00 CET | Press release
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
Novartis Pharma AG19.12.2025 20:30:06 CET | Press release
Novartis and US government reach agreement on lowering drug prices in the US
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
